Stockholm-based health technology startup Neko Health, co-founded by Spotify CEO Daniel Ek and entrepreneur Hjalmar Nilsonne, has secured a massive $700 million funding round from prominent global tech investors and longevity influencers. The landmark investment, announced this week, propels the company’s valuation deep into the multi-billion-dollar tier as it seeks to scale its AI-powered preventive healthcare scanning technology across Europe and North America.
The funding round represents one of the largest capital injections in the healthtech sector this year. Investors are increasingly betting on proactive, technology-driven diagnostics to alleviate the burden on strained global healthcare systems. Neko Health plans to use the capital to expand its clinic network, accelerate clinical trials, and further develop its proprietary artificial intelligence algorithms.
The Rise of Preventive Health Tech
Founded in 2018, Neko Health operated in stealth mode for five years before launching its first clinic in Stockholm in early 2023. The company’s core offering is a non-invasive, 10-minute full-body scan designed to detect early signs of cardiovascular disease, skin cancer, and metabolic disorders. By combining advanced sensor technology with machine learning, the startup aims to shift the medical paradigm from reactive treatment to early prevention.
Co-founder Daniel Ek has been vocal about his vision for healthcare, drawing parallels between the music industry’s digital transformation and the medical sector’s need for modernization. “We spend billions of dollars treating diseases once they have already progressed,” Ek stated during a recent industry summit. “Neko was built to change that by making early detection affordable and accessible to everyone.”
The demand for Neko’s services has been unprecedented. Upon its initial launch in Sweden, the company reported a waiting list of over 20,000 people within the first few weeks. This consumer enthusiasm reflects a broader societal shift toward longevity and proactive health optimization, popularized by high-profile wellness influencers and longevity researchers.
Inside the $700 Million Investment
The oversubscribed funding round attracted a diverse coalition of venture capital giants, sovereign wealth funds, and prominent figures in the longevity movement. While the company has not disclosed the exact valuation, industry insiders estimate Neko Health is now valued at several billion dollars. This positioning places it among the most valuable private healthtech companies globally.
Neko’s scanning booth utilizes more than 70 sensors to collect over 50 million data points on a patient’s skin, heart, blood vessels, and respiration in just minutes. The data is instantly analyzed by AI, and patients receive a comprehensive health report and a consultation with a physician immediately after the scan. The entire experience is designed to be seamless, contrasting sharply with the often fragmented and slow diagnostic processes in traditional clinics.
The capital injection will facilitate Neko’s ambitious international expansion. Following a successful pilot in London earlier this year, the company is preparing to open flagship clinics in major metropolitan areas across Germany, France, and eventually the United States. A significant portion of the funds will also be allocated to securing regulatory clearances from the U.S. Food and Drug Administration (FDA).
Industry Experts Weigh in on the Preventive Shift
Healthcare analysts view the mega-round as a watershed moment for the preventive medicine sector. “For decades, the financial incentives in healthcare have favored intervention over prevention,” says Dr. Elena Rostova, a healthcare analyst at European Tech Partners. “A $700 million round for a preventive scanning startup indicates that the investment community now sees a highly scalable, consumer-facing business model in keeping people healthy.”
However, the rapid rise of full-body scanning technology has also drawn scrutiny from some medical professionals. Critics warn that widespread scanning of asymptomatic individuals can lead to over-diagnosis, unnecessary anxiety, and a strain on secondary care systems due to false positives. To address these concerns, Neko Health has committed to publishing peer-reviewed data from its ongoing clinical studies to demonstrate the accuracy and clinical utility of its scans.
Data from Neko’s initial cohort of patients in Sweden showed that the scans successfully identified previously undiagnosed cardiovascular risks and early-stage melanomas in several asymptomatic individuals. These findings have bolstered the company’s position that early, AI-assisted detection can save lives and reduce long-term treatment costs for insurers and public health systems.
Scaling Global Diagnostics and What to Watch Next
The implications of Neko Health’s massive funding round extend far beyond the company’s immediate expansion. It signals a paradigm shift where consumer tech business models are successfully merging with clinical-grade diagnostics. As Neko scales, traditional healthcare providers may face pressure to integrate similar rapid-diagnostic technologies to meet consumer expectations for speed and transparency.
Looking ahead, the industry will closely watch how Neko navigates the complex regulatory environment of the United States. Securing FDA clearance for its AI diagnostic tools will be a critical hurdle. Additionally, the company’s ability to maintain data privacy while managing millions of highly sensitive biometric profiles will be paramount to sustaining consumer trust.
In the coming months, observers should watch for Neko’s upcoming partnerships with major health insurance providers. If the startup can secure reimbursement agreements, making the scans covered by standard health insurance rather than out-of-pocket expenses, it could democratize preventive diagnostics on a global scale. The race to define the future of proactive medicine is officially underway, with Neko Health firmly in the driver’s seat.
